Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Bright Minds Biosciences Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Bright Minds Biosciences Inc. (DRUG) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of Bright Minds Biosciences Inc. (NASDAQ: DRUG).
On November 2, 2026, Bright Minds announced that the U.S. Food and Drug Administration had placed a partial clinical hold on its investigational new drug application and related protocol for a planned Phase 2 BMB-101 trial in developmental and epileptic encephalopathies. According to the Company, the FDA cited toxicity identified in mice and inadequate pharmacokinetic and juvenile-toxicity data to support proposed pediatric enrollment. The investigation concerns whether Bright Minds adequately disclosed the relevant preclinical findings and data limitations to investors.
Following this news, Bright Minds’ stock price fell $28.78 per share, or approximately 52.4%, to close at $26.20 on November 2, 2026.
What Potential Securities Violations Is BG&G Investigating?
- Whether Bright Minds Biosciences Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether Bright Minds Biosciences Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Should Bright Minds Biosciences Inc. (DRUG) Investors Do?
How Is Bright Minds Biosciences Inc. (NASDAQ: DRUG) Stock Trading Today?
Interactive chart showing the weekly share price history of NASDAQ:DRUG (NASDAQ:DRUG).
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”